EUVIMEDEUVIMED entdecken
Crossref

Rescue of glutaric aciduria type I by GalNAc-conjugated siRNA against aminoadipate semialdehyde synthase

Yunhan Ma iD, Maiya Fujiwara iD, Natasha Murugan iD, Haoyue Zhang iD, Sabrina Belozerova iD, James Beasley iD, Cheryl K Peck iD, Timothy C Wood, Ashlee R Stiles, Sarah Young iD, Areeg El-Gharbawy iD, Mercedes Barzi iD und 3 weitere

Science Translational Medicine · 18.11.2026 · 18 (876)

DOI: 10.1126/scitranslmed.aej2067 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Science Translational Medicine, erschienen am 18.11.2026. Verfasst von Yunhan Ma und 14 weiteren Autor:innen. Beteiligte Einrichtung: Alice and Y. T. Chen Center for Genetics and Genomics, Division of Medical Genetics, Department of Pediatrics, Duke University Medical Center, Durham…. Hauptthemen laut MEDLINE: RNA, Small Interfering, Amino Acid Metabolism, Inborn Errors, Brain Diseases, Metabolic, Acetylgalactosamine. Die Arbeit nennt 18 Literaturangaben. Gefördert von: National Cancer Institute, National Institute of Diabetes and Digestive and Kidney Diseases, Alnylam Pharmaceuticals.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Glutaric aciduria type I (GA-1) is a severe metabolic disorder caused by a deficiency of glutaryl-CoA dehydrogenase (GCDH), leading to accumulation of organic acids in the brain and resulting in striatal injury and progressive movement disorders. Although early diagnosis and dietary management reduce risk, one-third of patients still develop debilitating neurological complications. We previously demonstrated that liver-specific deletion of aminoadipate semialdehyde synthase (AASS), an upstream enzyme in lysine degradation, is a promising therapeutic strategy. Here, we tested an N -acetylgalactosamine (GalNAc)–conjugated siRNA against Aass . Treatment of neonatal Gcdh −/− mice rescued lethality and improved the brain pathology while reducing toxic metabolites in the brain and other organs. Serum biomarkers, including glutaric acid, 3-hydroxyglutaric acid, and glutarylcarnitine, predicted neurological outcomes, supporting their use for therapeutic monitoring. Although systemic metabolite concentrations declined, their urinary excretion remained elevated, consistent with a renal washout phenomenon and preserved excretory capacity. These findings demonstrate the potential of liver-targeted small interfering RNA (siRNA) therapy as a treatment for GA-1.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

RNA, Small InterferingAmino Acid Metabolism, Inborn ErrorsBrain Diseases, MetabolicAcetylgalactosamineIntramolecular TransferasesAnimalsGlutaryl-CoA DehydrogenaseGlutaratesMice, KnockoutBrainMiceBiomarkersLiver

Substanzen

RNA, Small InterferingGlutaryl-CoA DehydrogenaseGlutaratesAcetylgalactosamineIntramolecular Transferasesglutaric acidBiomarkers

Autor:innen und Institutionen

  • Alice and Y. T. Chen Center for Genetics and Genomics, Division of Medical Genetics, Department of Pediatrics, Duke University Medical Center, Durham, NC 27710, USA.
  • Department of Biomedical Engineering (BME), Duke University Pratt School of Engineering, Durham, NC 27710, USA.
  • Biochemical Genetics Laboratory, Duke University Medical Center, Durham, NC 27710, USA.
  • Alnylam Pharmaceuticals, Cambridge, MA 02142, USA.
  • Biochemical Genetics Laboratory, Children's Hospital Colorado Anschutz Medical Campus, Aurora, CO 80045, USA.
  • Division of Gastroenterology, Department of Medicine, Duke University Medical Center, Durham, NC 27710, USA.

ORCID-Profile: Yunhan Ma, Maiya Fujiwara, Natasha Murugan, Haoyue Zhang, Sabrina Belozerova, James Beasley, Cheryl K Peck, Sarah Young, Areeg El-Gharbawy, Mercedes Barzi, Beatrice Bissig-Choisat, Leila Noetzli, Karl-Dimiter Bissig

Förderung

  • National Cancer Institute
  • National Institute of Diabetes and Digestive and Kidney Diseases
  • Alnylam Pharmaceuticals

Zitieren

APA

Ma, Y., Fujiwara, M., Murugan, N., Zhang, H., Belozerova, S., Beasley, J., Peck, C. K., Wood, T. C., Stiles, A. R., Young, S., El-Gharbawy, A., Barzi, M., Bissig-Choisat, B., Noetzli, L., & Bissig, K. D. (2026). Rescue of glutaric aciduria type I by GalNAc-conjugated siRNA against aminoadipate semialdehyde synthase. Science Translational Medicine, 18(876). https://doi.org/10.1126/scitranslmed.aej2067

Vancouver

Ma Y, Fujiwara M, Murugan N, Zhang H, Belozerova S, Beasley J, et al. Rescue of glutaric aciduria type I by GalNAc-conjugated siRNA against aminoadipate semialdehyde synthase. Science Translational Medicine. 2026;18(876). doi:10.1126/scitranslmed.aej2067

BibTeX
@article{Ma2026,
  author = {Ma, Yunhan and Fujiwara, Maiya and Murugan, Natasha and Zhang, Haoyue and Belozerova, Sabrina and Beasley, James and Peck, Cheryl K and Wood, Timothy C and Stiles, Ashlee R and Young, Sarah and El-Gharbawy, Areeg and Barzi, Mercedes and Bissig-Choisat, Beatrice and Noetzli, Leila and Bissig, Karl-Dimiter},
  title = {Rescue of glutaric aciduria type I by GalNAc-conjugated siRNA against aminoadipate semialdehyde synthase},
  journal = {Science Translational Medicine},
  year = {2026},
  volume = {18},
  number = {876},
  doi = {10.1126/scitranslmed.aej2067}
}
Kostenlos starten →